Article
Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients.
European journal of clinical pharmacology - 1 Sept 2006
Varsaldi Federica, Miglio Gianluca, Scordo Maria Gabriella, Dahl Marja-Liisa, Villa Laura Maria, Biolcati Aldo, Lombardi Grazia
Abstract excerpt
OBJECTIVE: The aims of this study were to evaluate the impact of the CYP2D6 polymorphism on both the steady-state plasma concentrations (Cp) and the clinical outcome of donepezil, a selective acetylcholinesterase inhibitor used in the treatment of Alzheimer's disease (AD). METHODS: Forty-two patients of Caucasian ethnicity affected by probable AD were included in the study. All had been receiving therapy with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
